Every material Form 8-K Amphstar Pharmaceuticals filed with the SEC in 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Amphastar reported third-quarter 2026 net revenues of $207.6 million, up 8% from $191.8 million a year earlier. GAAP net income was $37.8 million, or $0.87 per diluted share, compared with $17.4 million, or $0.37, in the prior-year quarter, which included a $23.1 million litigation provision. Gross margin fell to 48.0% from 51.4%, and the board authorized a $50 million increase to the share buyback program.
Net revenues $207.6 million vs $191.8 million in Q3 2025, up 8%
GAAP diluted EPS $0.87 vs $0.37; adjusted non-GAAP diluted EPS $1.14 vs $0.93
Gross margin 48.0% vs 51.4%, mainly from lower average selling prices and higher remediation-related manufacturing costs
Board authorized a $50 million increase to the share buyback program on November 4, 2026
Amphastar reported second-quarter 2026 net revenues of $183.9 million, up 5% from $174.4 million a year earlier, and gross margin rose to 50.8% from 49.6%. GAAP net income fell slightly to $30.3 million, though diluted EPS rose to $0.67 from $0.64 on a lower share count, and income from operations declined to $39.7 million from $42.2 million. Shareholders face a $100.0 million milestone payment to Eli Lilly due in the third quarter of 2026.
Net revenues $183.9 million vs. $174.4 million a year earlier; glucagon sales fell 42% to $11.9 million
GAAP net income $30.3 million, or $0.67 diluted EPS, vs. $31.0 million, or $0.64, in Q2 2025
Adjusted non-GAAP net income $40.8 million, or $0.91 per diluted share, vs. $0.85 a year earlier
BAQSIMI first annual net sales milestone of $175.0 million triggers a $100.0 million payment to Lilly due Q3 2026
Amphastar Pharmaceuticals increased its board from 10 to 11 seats on July 9, 2026, and appointed Anthony Pierce as a Class III director, effective immediately. The board deemed him independent under Nasdaq listing standards, and he has no committee assignments at this time.
Board size increased from 10 to 11 directors; Pierce appointed effective immediately
Pierce's term runs until the 2028 annual meeting of stockholders
Annual cash retainer of $55,000, pro-rated for his start date
Initial equity grant with aggregate grant date fair value of $300,000, split 50% restricted stock units and 50% stock options, vesting on the first anniversary
Amphastar reported first-quarter 2026 results with net revenues essentially flat at $171.2 million, up $643 thousand from a year earlier. GAAP net income fell to $6.4 million, or $0.14 per diluted share, from $25.3 million, or $0.51, as gross margin dropped to 41.1% from 50.0%. For shareholders, the flat sales and sharply lower profit point to weaker earnings, with the company citing higher cost of revenues and research and development spending.
Net revenues were $171.2 million versus $170.5 million in Q1 2025, a 0% change.
GAAP net income was $6.4 million ($0.14 per diluted share) versus $25.3 million ($0.51) a year earlier.
Adjusted non-GAAP net income was $19.5 million ($0.42 per diluted share) versus $36.9 million ($0.74).
BAQSIMI sales fell 15% to $32.4 million, and glucagon sales fell 56% to $9.2 million; cash flow from operations was $47.8 million.
On March 3, 2026, Amphastar entered employment agreements with Jacob Liawatidewi, Executive Vice President of Corporate Administration Center, Secretary and board member, and Rong Zhou, Senior Executive Vice President of Production Center. The agreements set base salaries, target bonuses, and severance terms that would apply if an executive is terminated without cause, does not have a renewal, or resigns for good reason, with enhanced terms after a change in control.
Liawatidewi base salary is $525,800 with a target annual bonus of 55% of salary; Zhou base salary is $590,000 with a target bonus of 53% of salary.
On a qualifying termination, each executive receives a lump sum of two times the highest base salary of the prior 12 months plus the average annual bonus for the two most recent fiscal years, up to 12 months of health premium payments, and
Terms within one year after a change in control add a second lump-sum payment of the same formula and an extra 12 months of health premium payments.
The agreements have a one-year initial term with automatic one-year renewals; the form of agreement is filed as Exhibit 10.1, and the report is dated March 6, 2026.
Amphastar's Chinese subsidiary ANP signed a five-year supply agreement with Nanjing Letop Biotechnology on March 3, 2026, for chemical intermediates, with no minimum purchase obligation. The company also amended a contract research agreement with Nanjing Hanxin, raising its total cost by about $0.6 million. Both counterparties are linked to the company's CEO and Chairman through family ownership, and the company states neither agreement is material to its financial condition or results of operations.
Supply Agreement with Letop signed March 3, 2026, for five years; ANP has no minimum purchase obligation
Contract Research Amendment with Hanxin raises total cost by about $0.6 million, shifting work from AMP-107 to AMP-105
Letop and Hanxin are related parties; Audit Committee evaluated and approved both deals
Company states neither agreement is material to its financial condition or results of operations
Amphastar reported fourth-quarter and full-year 2025 results on February 26, 2026. Revenue, GAAP net income and diluted EPS declined from 2024 in both periods, and the release does not include financial guidance for 2026. Full-year results include a $23.1 million litigation provision, and glucagon sales fell 45% in the fourth quarter on lower average selling prices and unit volumes.
Q4 2025 net revenues were $183.1 million, down 2% from $186.5 million in Q4 2024
Q4 GAAP diluted EPS was $0.51 vs. $0.74; adjusted non-GAAP diluted EPS was $0.73 vs. $0.92
Full-year 2025 net revenues were $719.9 million vs. $732.0 million; GAAP diluted EPS was $2.03 vs. $3.06
BAQSIMI sales rose 46% to $185.4 million for the full year, while glucagon sales fell 36% to $69.1 million
Amphastar entered into an exclusive license agreement with Nanjing Hanxin Pharmaceutical Technology on January 6, 2026, for AMP-110, a fully synthetic corticotropin compound in early-phase human clinical development, covering the United States and Canada. Hanxin is controlled by family members of Amphastar's CEO and Chairman, so the agreement and two related amendments are related party transactions, and the company says the amendments are not expected to be material.
Amphastar made a $2 million upfront payment to Hanxin, with up to $14 million in development milestones and up to $75 million in sales milestones.
Royalties payable by Amphastar to Hanxin are capped at $7.5 million per calendar year and $60 million in total accumulated.
Dr. Jack Zhang and Dr. Mary Luo and certain family members own a majority of Hanxin; the Audit Committee approved the distribution and manufacturing amendments.
The Distribution and Manufacturing Amendments expand territories; their value is not determinable until sales occur in the expanded regions.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Amphstar Pharmaceuticals filing is on SEC EDGAR ↗. 8-K briefs of other companies →